Daraxonrasib: A Promising New Treatment for Pancreatic Cancer

Patients with advanced pancreatic cancer are finding hope in a new drug called daraxonrasib. Dr. Zev Wainberg from UCLA Health’s GI Oncology Program has been leading a clinical trial for this drug, and the response has been overwhelming. Many patients prefer it over chemotherapy, which had started to fail for them.

During the trial, daraxonrasib doubled the survival time for patients with advanced pancreatic cancer. On average, they lived for 13.2 months compared to 6.7 months with chemotherapy. This news was presented at the American Society of Clinical Oncology’s meeting in Chicago and published in the New England Journal of Medicine.

Revolution Medicines, the company behind daraxonrasib, is optimistic about its potential. Dr. Rachna Shroff from the University of Arizona Cancer Center praised its impact on her field. The drug targets a mutation in the KRAS gene found across various cancers, not only pancreatic cancer. This includes lung, colorectal, ovarian, endometrial, and bile duct cancer.

Dr. Brian Wolpin of Dana-Farber Cancer Institute believes daraxonrasib opens opportunities for treating other cancers. The FDA has fast-tracked the drug’s approval for pancreatic cancer, allowing its use outside of clinical trials. Although a timeline for filing has not been provided, Revolution Medicines is prioritizing the approval process.

Pancreatic cancer is often diagnosed at a stage where surgery isn’t possible. Chemotherapy usually offers minimal benefits, with survival averaging around 6 months. Only 3% of patients survive beyond five years. Daraxonrasib is providing new possibilities for patients like Debby Orcutt, whose tumors significantly decreased after she began taking the medication.

The drug operates by targeting the KRAS mutation, which keeps cancer cell growth uncontrollable. Despite challenges in drugging the mutation, scientists have succeeded through significant chemical advancements. Daraxonrasib acts as a ‘molecular glue,’ binding with the mutation and disrupting its function.

While daraxonrasib does not cure cancer, it represents a critical step in treatment. Revolution Medicines is developing additional RAS inhibitors, seeking to extend the drug’s effectiveness. Surprisingly, daraxonrasib benefits all patients with metastatic pancreatic cancer, not just those with the KRAS mutation.

Compared to chemotherapy, daraxonrasib is less toxic. Side effects include vomiting, diarrhea, mouth sores, and rash. Former Nebraska senator Ben Sasse described the rash as ‘nuclear.’ However, patients are willing to tolerate these for the benefit of the drug.

Debby Orcutt describes minimal side effects, emphasizing the drug’s life-saving potential. Her husband, Ron Orcutt, assists in managing her medication schedule. The couple cherishes their time together, with Debby’s experience reflecting a sense of renewed life.